These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 3311530)

  • 1. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.
    Moore MJ; Erlichman C
    Clin Pharmacokinet; 1987 Oct; 13(4):205-27. PubMed ID: 3311530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential applications of therapeutic drug monitoring in treatment of neoplastic disease by antineoplastic agents.
    Erlichman C
    Clin Biochem; 1986 Apr; 19(2):101-6. PubMed ID: 3518986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic drug monitoring.
    Henner WD
    Clin Lab Med; 1987 Sep; 7(3):625-39. PubMed ID: 3308299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
    Levêque D; Becker G
    Expert Opin Drug Saf; 2019 Nov; 18(11):1009-1015. PubMed ID: 31478396
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring in cancer chemotherapy.
    Bach DM; Straseski JA; Clarke W
    Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target concentration intervention in oncology: where are we at?
    Saleem M; Dimeski G; Kirkpatrick CM; Taylor PJ; Martin JH
    Ther Drug Monit; 2012 Jun; 34(3):257-65. PubMed ID: 22585183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacokinet; 2005; 44(2):147-73. PubMed ID: 15656695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of commonly used anticancer drugs.
    Balis FM; Holcenberg JS; Bleyer WA
    Clin Pharmacokinet; 1983; 8(3):202-32. PubMed ID: 6189661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy in newborns and preterm babies.
    Veal GJ; Boddy AV
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):243-248. PubMed ID: 22464845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory monitoring in oncology.
    Duong CD; Loh JY
    J Oncol Pharm Pract; 2006 Dec; 12(4):223-36. PubMed ID: 17156594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring in cancer--are we missing a trick?
    Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
    Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer, clinical pharmacology, and aging.
    Hutchins LF; Lipschitz DA
    Clin Geriatr Med; 1987 Aug; 3(3):483-503. PubMed ID: 3308046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-toxicity models in oncology.
    Adamina M; Joerger M
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.
    Dumez H; Guetens G; De Boeck G; Highley MS; Maes RA; van Oosterom AT; de Bruijn EA
    Clin Chem Lab Med; 2004; 42(11):1219-27. PubMed ID: 15576286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.
    Liu JJ; Kestell P; Findlay M; Riley G; Ackland S; Simpson A; Isaacs R; McKeage MJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):677-82. PubMed ID: 15554907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L
    J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.